Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC

ConferencetrontinemabElecsys pTau217Elecsys pTau181Positive

AI Analysis

Summary

Roche will present 18 oral and poster presentations on its Alzheimer's disease portfolio at AAIC 2026 in London, including data on trontinemab and blood-based biomarker tests (pTau217 and pTau181) for disease diagnosis and management.

Importance:5/10

Sentiment:

0.30

Alzheimer's diseasediagnosticsconference presentationbiomarkersneurodegenerative disease

Related Companies

$RHHBY

Read the original article

Published by GlobeNewswire Pharma on July 7, 2026 5:00 AM

Read Original